Fibrinogen-coated albumin microcapsules

Drug Profile

Fibrinogen-coated albumin microcapsules

Alternative Names: FAMs; Fibrinogen microcapsules; Synthocytes

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Quadrant Healthcare
  • Developer ProFibrix; Quadrant Healthcare
  • Class Acute-phase proteins; Albumins; Antihaemorrhagics; Blood coagulation factors; Coagulants; Protein precursors
  • Mechanism of Action Fibrinogen replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Thrombocytopenia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Thrombocytopenia in Denmark (IV, Injection)
  • 05 Aug 2013 ProFibrix has been acquired by The Medicines Company
  • 13 Oct 2008 Preclinical for Thrombocytopenia in Denmark (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top